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Fotoquimioterapia no Eritema Anular Centrifugo 
Recalcitrante: Uma Opção Terapêutica Promissora?     
Bruno Duarte1, Filipa Rocha Páris1, Joana Cabete1
1Dermatology Department, Hospital de Santo António dos Capuchos – Centro Hospitalar de Lisboa Central, Lisbon, Portugal
RESUMO – O eritema anular centrífugo. é uma dermatose de etiologia desconhecida e geralmente auto-limitada. Apesar 
disto, alguns casos tendem para a cronicidade, especialmente quando não é identificado o estímulo causal. Estes últimos 
casos são geralmente desafiantes do ponto de vista terapêutico.
Um homem de 24 anos recorreu à consulta de Dermatologia por placas policíclicas múltiplas, com crescimento radial, 
bordo infiltrado e clareamento central, localizadas nos glúteos, antebraços e coxas com 3 anos de evolução. A correlação 
clinico-patológica conduziu ao diagnóstico de eritema anular centrifugo. Foram excluídas causas secundárias. O tratamen-
to com corticoides tópicos e sistémicos não ofereceu qualquer melhoria, e o doente estava relutante em tentar imunossu-
pressores sistémicos orais. Optou-se assim pela fotoquimioterapia. Uma melhoria muito significativa foi verificada desde o 
primeiro tratamento, ficando o doente completamente limpo ao sétimo tratamento. Aos 3 meses de follow-up, mantem-se 
em remissão.
No nosso conhecimento, relatamos o primeiro caso de eritema anular centrífugo tratado de forma bem-sucedida com foto-
quimioterapia. Enfatizamos o papel que esta modalidade terapêutica clássica ainda pode, e deve ocupar no tratamento de 
dermatoses inflamatórias refratárias, como o eritema anular centrífugo.
PALAVRAS-CHAVE – Eritema/tratamento; Fotoquimioterapia. 
Photochemotherapy for Recalcitrant Erythema 
Annulare Centrifugum: A Promising Treatment 
Option?  
ABSTRACT – Erythema annulare centrifugum is a dermatosis of unknown aetiology which usually follows a self-limiting cour-
se. Nevertheless, some cases tend to chronicity, especially when a culprit stimulus is not found, and can be challenging to 
treat. A 24-year-old male presented with a 3-year history of persistent plaques with polycyclic outlines and an infiltrated rim 
on the forearms, buttocks and  thighs. After histopathological correlation, a diagnosis of erythema annulare centrifugum was 
therein made. Secondary causes were ruled out. Treatment with topical and systemic steroids provided no benefit, and the pa-
tient was reluctant to further systemic oral immunosuppression. Photochemotherapy was then attempted. A marked improved 
was observed since the first session, and the patient was clear by the 7th treatment. No adverse events were noted. The patient 
is still in remission at the 3rd month of follow-up.
To our knowledge, we report the first case of an erythema annulare centrifugum successfully treated with photochemotherapy. 
Our case highlights the potential of this time-honoured therapeutic modality to address chronic and debilitating cases of this 
figurate dermatosis.
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Erythema annulare centrifugum (EAC) is a figura-
te erythema which represents a delayed hypersensitivi-
ty reaction.1,2 In many cases the offending insult cannot 
be found and eliminated, leading to a chronic course for 
which effective therapies are lacking. Herein, we describe 
the complete resolution of a recalcitrant EAC using photo-
chemotherapy, a long-established treatment in the derma-
tological armamentarium, yet unexplored for this purpose. 
CASE REPORT
A 24-year-old, skin type III Caucasian male presented 
with a 3-year history of persistent, mildly pruritic plaques 
with polycyclic outlines and an infiltrated rim on the forear-
ms, buttocks and thighs (Fig. 1A,1C,1E). The lesions began 
as small papules which expanded centrifugally through a 
leading edge, many of them with a trailing scale. Patient’s 
medical past and general physical exam were unremarka-
ble. Regular or sporadic use of medications was denied. A 
skin biopsy showed perivascular and periadnexal lympho-
cytic infiltrates with an acanthotic epidermis, parakerato-
sis, pitiriasiform vesiculation and scant spongiosis (Fig. 2). 
Clinicopathological correlation established a diagnosis of 
EAC. An extensive laboratorial (blood cell count and diffe-
rential, routine biochemistry, serum electrophoresis, pro-
tein count, viral serologies, erythrocyte sedimentation rate, 
thyroid panel, ANA and rheumatoid factor, stool tests for 
bacterial, viral and parasitic pathogens, interferon gamma 
release assay for tuberculosis) revealed no abnormalities. 
Further investigation, including mycological and imaging 
tests were also unremarkable. Topical and systemic steroi-
ds were tried for a full year with little success and ensuing 
immediate relapses. Doxycycline 200 mg/daily provided 
mild benefit. The patient was reluctant to try oral or injecta-
ble immunomodulators. Treatment with psoralen ultravio-
let-A (PUVA) twice weekly was then attempted (initial/final 
dose: 2.0/8.0J cm2, respectively). A major improvement 
was progressively observed to a complete response on the 
7th session (Fig. 1B,1D,1F). No side effects were observed. 
The patient was utterly satisfied. PUVA was stopped after 
the 20th treatment and no relapses have so far been obser-
ved on short follow-up (six months).
DISCUSSION
In many cases, EAC follows a self-limiting course. In 
others, a culprit stimulus can be found, either an infection, 
a drug, an underlying malignancy or any other disorder 
from a wide spectrum of putative associations.2 Addressing 
the noxious stimuli usually leads to remission and hence 
is the therapy cornerstone. Albeit the apparent favourable 
prognosis, there is a subset of patients who follow a chro-
nic, debilitating course for which symptomatic treatment 
is desired. Topical and systemic steroids are widely used, 
but long-term risks and relapses following discontinuation1 






demand steroid-sparing therapeutic options. Consensus 
treatment guidelines are unfortunately inexistent for recal-
citrant cases. Systemic immunomodulators are often given 
but may fail to provide relief.3 Erythromycin was reported 
as temporarily effective,1 while a case documented a com-
plete response with oral metronidazole4 and another case 
reported full remission with oral doxycycline therapy.5 Eta-
nercept 25 mg biweekly induced complete clearance over 
a 6-month period in one patient.2
Phototherapy is a time-honoured therapeutic moda-
lity in many dermatological conditions,6 but evidence for 
its application in EAC is scarce. Narrow-band ultraviolet-
-B combined with calcipotriol ointment for 4-weeks led to 
remission in one case.7 Natural sunlight led to clearance 
in 2 cases.8 To our knowledge, this is the first report of 
a refractory, debilitating EAC case successfully managed 
with PUVA. A Th1-mediated pathogenesis has been spe-
culated, in which tumour necrosis factor alfa (TNF-α) and 
associated cytokines play a critical role.2 Indeed, inflam-
matory dermatoses are successfully treated by photothe-
rapy through an interplay of photobiologic mechanisms,6 
such as the down-regulating an overreactive, dysregulated 
Th1/Th17 axis and its orchestrated inflammatory cascade, 
including TNF-α. 
We opted for photochemotherapy as, for this condition, 
it might be more effective than NB-UVB. Moreover, the twi-
ce-weekly PUVA regimen suited better the patient’s busy 
schedule than its thrice-weekly NB-UVB, which reflected in 
a high-adherence rate.  EAC histopathology often reveals 
dermal lymphocytic infiltrates, especially on its deep va-
riant.9 Ultraviolet-A irradiation allows for deeper, mid- to 
deep-dermal immunomodulation10 which may superiorly 
target these immune cells. Furthermore, photochemothe-
rapy leads to faster and longer lasting remission in other 
inflammatory cutaneous diseases.11 Nevertheless, an unfa-
vourable response to PUVA was previously reported in an 
isolated report,12 albeit decisive therapeutic variables such 
as treatment adherence and dose regimen were not inclu-
ded in the report. 
In summary, the rapid resolution, excellent tolerabili-
ty and sustained response makes PUVA an encouraging 
treatment for EAC. Despite a single report, we believe pho-
tochemotherapy should be further explored to ascertain 
the efficacy and long-term clearance rates of EAC with this 
promising and dermatologic-specific approach.
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